



Tumor Immune Microenvironment: A Holistic Approach Workshop

April 21-22, 2022 • San Diego and Virtually

#SITCworkshop




Society for Immunotherapy of Cancer



Lymphatic transport, immune surveillance, and immune evasion

Amanda W. Lund, PhD

Friday April 22, 2022




Associate Professor, Ronald O. Perelman Department of Dermatology,
Department of Pathology, and Laura and Isaac Perlmutter Cancer
Center


Amanda W. Lund, PhD
No Disclosures

A background network diagram consisting of numerous light purple circular nodes connected by thin, light purple lines. The nodes are distributed across the slide, with a higher density in the center and lower density towards the edges. The lines represent connections between the nodes, creating a complex web-like structure.

Microenvironmental barriers to T cell-based therapies




Tissue/Tumor distribution of T cells depends on coordinated vascular and tissue signals




CD8⁺ T cells are restricted to the activated peritumoral stroma

Human Cutaneous Primary Melanoma




S100 CD8 PDPN AQP1 CD68


Primary Murine Melanoma




Peritumoral




Intratumoral





DAPI CD8 LYVE1




Dermal lymphatic vessels limit CD8⁺ T cell accumulation in melanoma







Lymphatic endothelial cells are transcriptionally reprogrammed in the tumor microenvironment




Lymphatic-secreted CXCL12 sequesters CD8⁺ T cells in the tumor periphery




Functional CD8⁺ T cells exit the tumor microenvironment




Tumor-specific, functional CD8⁺ T cells are expelled from the tumor microenvironment




Linking migration potential and T cell state in tumors






Antigen encounter regulates CXCL12 sensitivity and migration ex vivo




CXCR4 inhibition synergizes with immune checkpoint blockade in immunogenic melanoma



Lymphatic-secreted CXCL12 restricts CD8⁺ T cell-mediated tumor control in immunogenic melanoma



The lymphatic vasculature as a dynamic, immunological scaffold and immunotherapy target



Lund et al *Cell Reports* 2012
 Lund et al *JCI* 2016
 Loo, Nelson et al *Cell Reports* 2017
 Lane et al *JEM* 2018
 Steele et al *JOVE* 2019
 Churchill et al *JEM* 2022
 Steele et al *under review* 2022

LEVERAGE LYMPHATIC VASCULATURE FOR CANCER IMMUNOTHERAPY



The Lund Lab [@thelundlab] – FUNDED POSTDOCS Available



Current Lab Members:

Maria Steele, PhD
Haley du Bois
Taylor Heim
Filio Karakousi
Tenny Mudianto
Katie Ventre
Alex Figueroa
Annie Chen
Elle da Silva
Sunny Son

NYU Langone Health:

Iman Osman, M.D.
Itai Yanai, PhD.
Eva Hernando-Monge, Ph.D.
Markus Schober, Ph.D.

Oregon Health & Science University:

Jeffrey C. Nolz, PhD.
Lisa M. Coussens, PhD.
Sancy A. Leachman, M.D., PhD.

Lab Alumni: Chiso Ahanotu, Aissatou Bah, Jamie Booth, Alec Breazeale, Madeline Churchill, Ian D. Dryg, PhD, Julia Femel, PhD, Ryan Lane, PhD, Chris Loo, PhD, Sofia Loprinzi-Hardin, Cameron Hill, Nicholas Nelson, Audre May, Joseph Scarpelli, Reed Shelby, Melanie Staffenson, Aubrey Pierce



NIH/NCI R01 CA238163 (Lund)
NIH/NIAMS ARO80068 (Lund)

NIH/NIAID T32-A1100853 (Heim)
NIH/NIGMS T32GM136542 (du Bois)
NIH/NCI 5T32CA106195-15 (Loo, Lane, Steele)

